机译:Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
St Orsola Malpighi Univ Hosp, Inst Hematol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy;
Univ Catania, Dept Sci Med Chirurg & Tecnol Avanzate GF Ingrass, Catania, Italy;
Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Div, Milan, ItalySan Gerardo Hosp, ASST, Hematol Div, Monza, ItalyUniv Padua, Unit Hematol & Clin Immunol, Padua, ItalyAzienda USL IRCCS Reggio Emilia, Dept Hematol, Reggio Emilia, ItalyUniv Brescia, ASST Spedali Civili Brescia, Dept Clin & Expt Sci, Unit Blood Dis & Stem CellsAzienda Osped Bianchi Melacrino Morelli, Div Hematol, Reggio Di Calabria, ItalyOsped S Eugenio, Div Hematol, Rome, ItalyIRCCS AOU San Martino IST, Dept Internal Med DiMI, Clin Hematol, Genoa, ItalyFriedrich Schiller Univ, Med Ctr, Internal Med Hematol & Oncol 2, Jena, GermanyAzienda Osped Univ Parma, Div Hematol, Parma, ItalyAUSL Piacenza, Div Hematol, Piacenza, ItalyOsped Riuniti Marche, AORMN Azienda Osped, Haematol & Haematopoiet Stem Cell Transplant Ctr, PesaroUniv Ferrara, Div Hematol, Ferrara, ItalyUniv Udine, Div Hematol & BMT, Dept Med Area, Udine, ItalyUniv Verona, Sect Hematol, Dept Med, Verona, ItalyCitta Salute & Sci Hosp, Div Hematol, Turin, ItalyUniv Sapienza, Div Cellular Biotechnol & Hematol, Rome, Italy;
blast phase; myelofibrosis; outcome; risk factors; ruxolitinib;